Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion-Reference-Cited by-同舟云学术

Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion

Published:2023-03 Issue:3 Volume:23 Page:e150-e163
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Zhang Yumeng^ORCID,Nguyen Lynn,Lu Chuanyi M.,Wang Endi^ORCID,Lauw Marietya I.S.,Ball Somedeb,Dong Ning,Moscinski Lynn,Chan Onyee^ORCID,Yun Seongseok,Sallman David,Sokol Lubomir,Shah Bijal,Knepper Todd^ORCID,Lancet Jeffery,Komrokji Rami,Padron Eric,Kuykendall Andrew,Zhang Ling

Funder

Moffitt Cancer Center

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference29 articles.

1. Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2;Pozdnyakova;Am J Clin Pathol,2021

2. Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood. 2017 Feb 9;129(6):704-714. doi: 10.1182/blood-2016-10-695973. Epub 2016 Dec 27. PMID: 28028030.

3. Swerdlow SH. WHO Classification of tumours of haematologic and lymphoid tissues : precursor lymphoid neoplasms. 2008 2008:168-178.

4. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia;Arber;Blood,2016

5. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms;Khoury;Leukemia,2022

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management;American Journal of Hematology;2024-03-29

2. Antineoplastics;Reactions Weekly;2023-08-19

3. Myeloproliferative Neoplasm Driven by ETV6-ABL1 in an Adolescent with Recent History of Burkitt Leukemia;Current Oncology;2023-06-21